PGEN - Total Utang marang Modal Precigen Corp

Logo perusahaan publik Precigen, Inc. (PGEN)

Precigen, Inc. (PGEN) is developing the UltraVector platform to combat oncology while awaiting FDA approval for the PRGN-2012 vaccine. The financial leverage ratio (total debt-to-equity) illustrates this trajectory, where 2.21 defines the current status of the parameter. The UltraCAR-T strategy accelerates the creation of personalized therapies; however, the reliance on respiratory drug trials and high R&D expenditures necessitate strict liquidity control.

PGEN: Total Utang marang Modal Precigen 04.07.2022 - 29.10.2026

Rincian analitis perusahaan Precigen, Inc.

- rega lan prakiraan konsensus rega:
Bagan rega Precigen|PGEN - Bagan tingkat prakiraan
- statistik kapitalisasi pasar:
Kapitalisasi pasar Precigen|PGEN - Nilai Dipunlarasaken Utang lan Kas
- indikator kapitalisasi buku:
Nilai Buku saben Saham Precigen|PGEN - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku precigen.com|PGEN - Nilai Agregat Aset
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas Precigen, Inc.|PGEN - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Precigen, Inc.|PGEN - Gunggung utang perusahaan|Utang marang nilai buku Precigen|PGEN - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Precigen
Analisis dhasar perusahaan:Precigen
Barang utama Precigen Corp

Precigen, Inc. (PGEN) is developing a high-tech synthetic biology and gene programming ecosystem for cancer therapy. This financial stability ratio (debt-to-equity) compares the issuer's total liabilities to its net assets. The trend of this metric reflects the extent to which capital-intensive developments rely on borrowed funds. Rising values signal a risk of over-leverage, which reduces the business's margin of safety. Investors evaluate this tool to determine the company's debt load.

Analisis pesaing Precigen, Inc.

Utang marang Ekuitas argenx|BioNTech Inc. - Utang Agregat marang Ekuitas|Total Utang marang Modal ABVX|ADMA (ADMA Corp) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal PTGX (Protagonist Therapeutics)|Total Utang marang Modal immunovant.com IMVT|KNSA - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi GRFS (Grifols SA)|Adaptive Biotechnologies Corp (ADPT) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Celldex Corp|AUPH (Aurinia Pharmaceuticals) - Total Utang marang Modal|Total Utang marang Modal biocryst.com|Rasio Total Utang marang Ekuitas VERA (Vera Therapeutics)|DNTH (Dianthus Therapeutics Inc) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal PHVS (Pharvaris Corp)|Koefisien Total Utang marang Modal AbCellera (ABCL)|TRML - Utang marang Ekuitas|pharming.com (PHAR) - Rasio Total Utang marang Ekuitas|Nektar Therapeutics Inc. (NKTR) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Upstream Bio, Inc.|Rasio Total Utang marang Ekuitas ZBIO|Total Utang marang Modal Immunome Bio|Utang marang Ekuitas Gossamer Bio, Inc. (GOSS)|kalvista.com - Rasio Utang marang Ekuitas|Total Utang marang Modal SEPN (Septerna)|Pieris Pharma (PVLA) - Utang marang Modal|SVRA - Utang marang Ekuitas|Utang Agregat marang Ekuitas RIGL|AnaptysBio, Inc. (ANAB) - Utang marang Ekuitas|astriatx.com - Rasio Kabeh Utang marang Dana Pribadi|ENGN (enGene) - Total Utang marang Modal|Utang marang Modal RAPT Therapeutics Inc. RAPT|Total Utang marang Modal JBIO|Rasio Total Utang marang Ekuitas Aclaris Therapeutics, Inc ACRS|Total Utang marang Modal KYTX (Kyverna Therapeutics)|Koefisien Total Utang marang Modal tizianalifesciences.com (TLSA)|Cabaletta Bio - Total Utang marang Modal|Rasio Utang marang Modal Ventyx Biosciences Inc. (VTYX)|THTX: Total Utang marang Modal|Utang marang Modal Avalo Therapeutics Inc (AVTX)|Utang marang Ekuitas Eledon Pharmaceuticals|Rasio Utang marang Ekuitas AGEN (agenusbio.com)|Rasio Total Utang marang Ekuitas CLYM (Climb Bio)|ZURA (Zura Bio Ltd) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal ATYR (aTyr)|Koefisien Total Utang marang Modal Adagene Inc (ADAG)|IMA - Utang marang Ekuitas|STTK (Shattuck Labs, Inc.) - Rasio Utang marang Ekuitas|EQ: Total Utang marang Modal|Rasio Total Utang marang Ekuitas Connect Biopharma Holdings Limited|Rasio Total Utang marang Ekuitas IMUX|Atara Biotherapeutics Inc (ATRA) - Koefisien Total Utang marang Modal|Utang marang Ekuitas InflaRx N.V. (IFRX)|XFOR: Utang Agregat marang Ekuitas|Total Utang marang Modal ACET (Adicet Bio, Inc.)|Rasio Utang marang Modal Celularity Inc|INmune Bio Corp - Total Utang marang Modal|Utang marang Modal Barinthus Biotherapeutics Corp|Kezar Life Sciences (KZR) - Utang marang Ekuitas|Rasio Utang marang Ekuitas SABS|Utang marang Ekuitas Akari Therapeutics Plc|Enlivex Therapeutics, Ltd. - Utang Agregat marang Ekuitas|Total Utang marang Modal QTTB|GOVX (GeoVax Corp) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal EDSA (Edesa Biotech, Inc.)|Total Utang marang Modal ibioinc.com IBIO|CARM - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi XTLB (XTL Biopharmaceuticals Ltd)|boltbio.com (BOLT) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas HCW Biologics|APVO (Aptevo Therapeutics, Inc.) - Total Utang marang Modal|Total Utang marang Modal AIM ImmunoTech, Inc.|Rasio Total Utang marang Ekuitas ADTX (Aditxt)|GRI (GRI Bio Inc) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal XRTX (XORTX)|Koefisien Total Utang marang Modal Vyome Therapeutics (HIND)|REVB - Utang marang Ekuitas|indaptusrx.com (INDP) - Rasio Total Utang marang Ekuitas|Scinai Immunotherapeutics Ltd. (SCNI) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas CalciMedica|Rasio Total Utang marang Ekuitas AFMD|Total Utang marang Modal Allakos Therapeutics|Utang marang Ekuitas HOOKIPA Pharma Inc. (HOOK)|igmbio.com - Rasio Utang marang Ekuitas|Total Utang marang Modal ITOS (iTeos Therapeutics, Inc.)|Ocean Biomedical Inc (OCEA) - Utang marang Modal|TCBP - Utang marang Ekuitas|Utang Agregat marang Ekuitas THRD